




Figure S1. 4-PBA treatment resensitizes sunitinib-resistant ccRCC cells to sunitinib. (A) Cell viability curves of 786-O (sunitinib-resistant) and (B) Caki-1 (sunitinib-resistant) cell lines treated with increasing concentrations of sunitinib, with or without 4-PBA (2 mM) pretreatment. (C) Summary of IC₅₀ values of sunitinib in sunitinib-resistant 786-O cells with 4-PBA intervention. (D) Summary of IC₅₀ values of sunitinib in sunitinib-resistant Caki-1 cells with 4-PBA intervention. IC₅₀ values were calculated using GraphPad Prism. RD, resistant; SD, sensitive; 4-PBA, 4-phenylbutyrate; ccRCC, clear cell renal cell carcinoma.




	786-O	786-O-RD
IC ₅₀ (μM)	7.132	24.67



	786-O-R + 4-PBA
IC ₅₀ (μM)	13.22



	Caki	Caki-RD
IC ₅₀ (μM)	8.084	16.79



	Caki-R + 4-PBA
IC ₅₀ (μM)	9.76